Cancer Genetics (CGIX) Trading Down 5.6%

Cancer Genetics Inc (NASDAQ:CGIX) shares fell 5.6% on Thursday . The stock traded as low as $0.17 and last traded at $0.17. 524,818 shares were traded during trading, a decline of 74% from the average session volume of 2,053,687 shares. The stock had previously closed at $0.18.

Separately, ValuEngine upgraded Cancer Genetics from a “hold” rating to a “buy” rating in a report on Monday, February 4th.

The firm has a market capitalization of $10.28 million, a price-to-earnings ratio of -0.25 and a beta of 1.21. The company has a quick ratio of 0.36, a current ratio of 0.36 and a debt-to-equity ratio of 0.24.

Cancer Genetics (NASDAQ:CGIX) last issued its earnings results on Tuesday, April 16th. The medical research company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. The business had revenue of $6.80 million for the quarter. Cancer Genetics had a negative return on equity of 175.72% and a negative net margin of 77.28%.

Several institutional investors have recently modified their holdings of CGIX. Virtu Financial LLC acquired a new position in shares of Cancer Genetics during the 1st quarter worth approximately $48,000. Geode Capital Management LLC boosted its holdings in shares of Cancer Genetics by 106.6% during the 4th quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock worth $53,000 after purchasing an additional 114,448 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Cancer Genetics by 120.9% during the 1st quarter. Renaissance Technologies LLC now owns 2,007,229 shares of the medical research company’s stock valued at $482,000 after buying an additional 1,098,515 shares during the period. Vanguard Group Inc raised its position in shares of Cancer Genetics by 119.8% during the 3rd quarter. Vanguard Group Inc now owns 532,426 shares of the medical research company’s stock valued at $554,000 after buying an additional 290,146 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Cancer Genetics by 119.8% during the 3rd quarter. Vanguard Group Inc. now owns 532,426 shares of the medical research company’s stock valued at $554,000 after buying an additional 290,146 shares during the period. Institutional investors and hedge funds own 22.11% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Cancer Genetics (CGIX) Trading Down 5.6%” was originally posted by Rockland Register and is the property of of Rockland Register. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://rocklandregister.com/2019/05/30/cancer-genetics-cgix-trading-down-5-6.html.

Cancer Genetics Company Profile (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Featured Article: Economic Reports

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.